Condition
Skin Fibrosis
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT00781053Phase 2CompletedPrimary
Open Label Extension (OLE) for the Patients Treated in the ISD002-P144-07 Study
NCT00574613Phase 2CompletedPrimary
Efficacy and Safety Study of p144 to Treat Skin Fibrosis in Systemic Sclerosis
NCT00318175Phase 2Completed
Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis
Showing all 3 trials